PIK3CD and acute lymphoblastic leukemia: The degree of pathway inhibition in T-ALL cells exposed to more selective PI3K p110α, β, and δ inhibitors was more heterogenenous (Fig 3B–3D) and supports the idea that different leukemias show variable dependence on each PI3K isoform to activate Akt.